Spirapril is a non-sulfhydryl non-competitive inhibitor of angiotensin-converting enzyme (ACE). Spirapril is used clinically for its antihypertensive activity, lowering total peripheral vascular resistance and blood pressure and slightly increasing cardiac output and stroke volume.
| Cas No. | 94841-17-5 |
|---|---|
| Purity | ≥98% |
| Formula | C22H30N2O5S2 • HCl |
| Formula Wt. | 503.07 |
| IUPAC Name | (8S)-7-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-1,4-dithia-7-azaspiro[4.4]nonane-8-carboxylic acid |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | S6168 Info Sheet PDF |
|---|
Noble S, Sorkin EM. Spirapril. A preliminary review of its pharmacology and therapeutic efficacy in the treatment of hypertension. Drugs. 1995 May;49(5):750-66. PMID: 7601014.
Sybertz EJ, Watkins RW, Ahn HS, et al. Pharmacologic, metabolic, and toxicologic profile of spirapril (SCH 33844), a new angiotensin converting inhibitor. J Cardiovasc Pharmacol. 1987;10 Suppl 7:S105-8. PMID: 2485040.
